Research ArticleAccepted Article
Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation.
Maxime M.A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö-Schramm, Michelle E.A. Borm, Johannes W.J. Bijlsma, Johannes W.G. Jacobs, Floris P.J.G. Lafeber and Paco M.J. Welsing
The Journal of Rheumatology August 2020, jrheum.200067; DOI: https://doi.org/10.3899/jrheum.200067
Maxime M.A. Verhoeven
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Janneke Tekstra
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Jacob M. van Laar
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Attila Pethö-Schramm
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Michelle E.A. Borm
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Johannes W.J. Bijlsma
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Johannes W.G. Jacobs
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Floris P.J.G. Lafeber
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
Paco M.J. Welsing
From Rheumatology & Clinical Immunology, University Medical Center Utrecht, the Netherlands;F. Hoffmann-La Roche, Basel, Switzerland; Roche Nederland BV, Woerden, the Netherlands. Address correspondence to Maxime Marie Antoinette Verhoeven, PhD student, Department of Rheumatology & Clinical Immunology G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: m.m.a.verhoeven-15@umcutrecht.nl
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation.
Maxime M.A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö-Schramm, Michelle E.A. Borm, Johannes W.J. Bijlsma, Johannes W.G. Jacobs, Floris P.J.G. Lafeber, Paco M.J. Welsing
The Journal of Rheumatology Aug 2020, jrheum.200067; DOI: 10.3899/jrheum.200067
Accepted manuscript
Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation.
Maxime M.A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö-Schramm, Michelle E.A. Borm, Johannes W.J. Bijlsma, Johannes W.G. Jacobs, Floris P.J.G. Lafeber, Paco M.J. Welsing
The Journal of Rheumatology Aug 2020, jrheum.200067; DOI: 10.3899/jrheum.200067